Dec 30, 2020 at 7:00AM
Follow @omzitkus
Will consumers one day have a choice of which coronavirus vaccine they receive? Will the market for vaccines be overly complicated once other players join
Pfizer (NYSE:PFE) in earning Emergency Use Authorization or formal approvals? Dr. Bruce Gellin of the Sabin Vaccine Institute joined Olivia Zitkus and Corinne Cardina of Fool.com's Healthcare and Cannabis Bureau on a Dec. 18 episode of
Fool Live to talk about the challenges of vaccination logistics and the importance of information technology.
Olivia Zitkus: Turning from that, the vaccine race, to the vaccination challenge. What other issues do you see? Maybe either than cold chain two-dose schedule? Do you see any potential confusion if two similar vaccines are in the market?